Boosters and vaccines for adolescents boon for Pharmaniaga

Kenanga Research noted that after recording bumper profits in the third quarter of financial year 2021 (Q3FY21), there could be no sequential earnings growth for Pharmaniaga in the final quarter of this year, as any requirement for the Sinovac vaccine booster shot would potentially start from December.

KUALA LUMPUR: Further earnings growth for Pharmaniaga Bhd can come from the Sinovac vaccine’s potential to be approved as a booster shot and for adolescents, says Kenanga Research, although this will likely to be rolled out in the first half of 2022.

The research house noted that after recording bumper profits in the third quarter of financial year 2021 (Q3FY21), there could be no sequential earnings growth for Pharmaniaga in the final quarter of this year, as any requirement for the Sinovac vaccine booster shot would potentially start from December.